Seladelpar

Generic Name: Seladelpar

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃F_₃O_₅S

CAS Number: 851528-79-5

Unique Ingredient Identifier: 7C00L34NB9

Background: Seladelpar (MBX-8025) has been used in trials studying the treatment of Hyperlipidemia.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Phase 3

Recruiting

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Seladelpar
Drug: Placebo

First Posted Date: 2023-09-25

Last Posted Date: 2024-12-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 192

Registration Number: NCT06051617

Locations: 🇺🇸
SCPMG/Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸
California Liver Research Institute, Pasadena, California, United States
🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States

and more 45 locations

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

Phase 2

Completed

Conditions: Primary Sclerosing Cholangitis

Interventions: Drug: Placebo to match Seladelpar
Drug: Seladelpar

First Posted Date: 2019-07-18

Last Posted Date: 2021-06-03

Lead Sponsor: CymaBay Therapeutics, Inc.

Target Recruit Count: 1

Registration Number: NCT04024813

Locations: 🇺🇸
University of Colorado Denver and Hospital, Aurora, Colorado, United States
🇺🇸
Sutter Pacific Medical Foundation - California Pacific Medical Center, San Francisco, California, United States
🇺🇸
Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States

and more 7 locations

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: NASH - Nonalcoholic Steatohepatitis

Interventions: Drug: Placebos
Drug: Seladelpar

First Posted Date: 2018-06-11

Last Posted Date: 2022-09-15

Lead Sponsor: CymaBay Therapeutics, Inc.

Target Recruit Count: 181

Registration Number: NCT03551522

Locations: 🇺🇸
CymaBay Research Site, Rollingwood, Texas, United States

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: seladelpar

First Posted Date: 2017-12-11

Last Posted Date: 2018-05-18

Lead Sponsor: CymaBay Therapeutics, Inc.

Target Recruit Count: 32

Registration Number: NCT03369002

Locations: 🇺🇸
Vrg & Noccr, Knoxville, Tennessee, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy